| abstract |
Disclose the use of a class of 2-PMPA prodrugs that alter the tissue distribution of 2-PMPA for non-prostate tissue. The prodrugs of the present disclosure are selectively distributed to healthy tissues, including the kidneys, lacrimal glands, and salivary glands, which represent off-target binding and toxic sites for PSMA-targeted prostate cancer imaging agents and therapies. Therefore, 2-PMPA prodrugs can be used for pretreatment of PSMA-targeted cytotoxicity or radiation therapy, binding to the kidneys and salivary glands, and shielding from them. |